

Company Number: 395428

Casserly Pharmacy Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

Casserly Pharmacy Limited
CONTENTS

	Page
Director's Responsibilities Statement	3
Balance Sheet	4 - 5
Reconciliation of Shareholders' Funds	6
Notes to the Financial Statements	7 - 12

Casserly Pharmacy Limited

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 30 April 2025

The director made the following statement in respect of the unaudited financial statements:

"General responsibilities

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Director's declaration on unaudited financial statements


In relation to the financial statements which comprise the Balance Sheet, the Reconciliation of Shareholders' Funds and the related notes:

The director approves these financial statements and confirms that they is responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The director confirms that they has made available to Xeinadin, all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The director confirms that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 30 April 2025."

Signed on behalf of the board


Claire Casserly
Director

12 December 2025

Casserly Pharmacy Limited
BALANCE SHEET
as at 30 April 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	8	664,988	690,195
Investments	9	<u>798,828</u>	<u>739,449</u>
Current Assets			
Stocks	10	91,352	91,160
Debtors	11	71,117	73,196
Cash and cash equivalents		<u>905,894</u>	<u>629,588</u>
		<u>1,068,363</u>	<u>793,944</u>
Creditors: amounts falling due within one year	12	<u>(1,673,186)</u>	<u>(123,665)</u>
Net Current (Liabilities)/Assets		<u>(604,823)</u>	<u>670,279</u>
Total Assets less Current Liabilities		<u><u>858,993</u></u>	<u><u>2,099,923</u></u>
Capital and Reserves			
Called up share capital presented as equity		30	100
Retained earnings		<u>858,963</u>	<u>2,099,823</u>
Equity attributable to owners of the company		<u><u>858,993</u></u>	<u><u>2,099,923</u></u>

Casserly Pharmacy Limited
BALANCE SHEET

as at 30 April 2025

We as Director's of Casserly Pharmacy Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 12 December 2025 and signed on its behalf by:


Claire Casserly
Director

Casserly Pharmacy Limited
RECONCILIATION OF SHAREHOLDERS' FUNDS
as at 30 April 2025

	Called up share capital €	Retained earnings €	Total €
At 1 May 2023	100	1,912,208	1,912,308
Profit for the financial year	-	187,615	187,615
At 30 April 2024	100	2,099,823	2,099,923
Profit for the financial year	-	334,070	334,070
Redemption of equity shares	(70)	(1,574,930)	(1,575,000)
At 30 April 2025	30	858,963	858,993

Casserly Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

Casserly Pharmacy Limited is a company limited by shares incorporated in Ireland. Main Street, Abbeyleix, Co Laois, Ireland is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Director's Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

These financial statements are for this individual entity, the company does not have a parent or any subsidiaries.

The company number can be found on page three of these financial statements.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 30 April 2025 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102)

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

Cash flow statement

The company has availed of the exemption in FRS 102 from the requirement to prepare a Cash Flow Statement because it is classified as a small company.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Turnover on sale of goods is recognised when the company has transferred the significant risks and rewards of ownership in the goods, which usually takes place when the goods are physically delivered to the buyer.

Tangible assets and depreciation

Tangible assets are stated at cost less accumulated depreciation. Cost includes legal fees, stamp duty and other non-refundable purchase taxes, and also any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management, which can include the costs of site preparation, initial delivery and handling, installation and assembly, and testing of functionality.

The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	4% Straight line
Long leasehold property	-	12.5% Straight line
Fixtures, fittings and equipment	-	10% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable. Where such indicators are present, a review will be carried out of the residual value, depreciation method and useful lives, and these will be amended if necessary. Changes in depreciation rates arising from this review are accounted for prospectively over the remaining useful lives of the assets.

Casserly Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

Investment properties

Investment property is property held either to earn rental income, or for capital appreciation (including future re-development) or for both, but not for sale in the ordinary course of business.

Investment property is initially measured at cost, which includes the purchase cost and any directly attributable expenditure. Investment property is subsequently valued at its fair value at each reporting date, by professional external valuers. The difference between the fair value of an investment property at the reporting date and its carrying value prior to the valuation is recognised in the Profit and Loss Account as a fair value gain or loss. Any gain or loss on disposal of an investment property (calculated as the difference between the net proceeds from disposal and the carrying amount of the item) is recognised in the Profit and Loss Account.

Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Profit and Loss Account in the year in which it is receivable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

Borrowing costs

All borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company provides a range of benefits to employees, including paid holiday arrangements and defined contribution plans. Short term benefits, including holiday pay and other non-monetary benefits, are recognised as an expense in the period in which the service is received.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Casserly Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

continued

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Profit and Loss Account annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Profit and Loss Account when received.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Significant accounting judgements and key sources of estimation uncertainty

The preparation of these financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses.

Judgements and estimates are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

(a) Going Concern

The directors have prepared budgets and cash flows for a period of at least twelve months from the date of the approval of the financial statements which demonstrate that there is no material uncertainty regarding the company's ability to meet its liabilities as they fall due, and to continue as a going concern. On this basis the directors consider it appropriate to prepare the financial statements on a going concern basis. Accordingly, these financial statements do not include any adjustments to the carrying amounts and classification of assets and liabilities that may arise if the company was unable to continue as a going concern.

(b) Establishing useful economic lives for depreciation purposes of tangible fixed assets

Long-lived assets, consisting primarily of tangible fixed assets, comprise a significant portion of the total assets. The annual depreciation charge depends primarily on the estimated useful economic lives of each type of asset and estimates of residual values. The directors regularly review these asset useful economic lives and change them as necessary to reflect current thinking on remaining lives in light of prospective economic utilisation and physical condition of the assets concerned. Changes in asset useful lives can have a significant impact on depreciation and amortisation charges for the period. Detail of the useful economic lives is included in the accounting policies.

(c) Providing for doubtful debts

The company makes an estimate of the recoverable value of trade and other debtors. The company uses estimates based on historical experience in determining the level of debts, which the company believes, will not be collected. These estimates include such factors as the current credit rating of the debtor, the ageing profile of debtors and historical experience. Any significant reduction in the level of customers that default on payments or other significant improvements that resulted in a reduction in the level of bad debt provision would have a positive impact on the operating results. The level of provision required is reviewed on an ongoing basis and has been disclosed in the notes to the financial statements.

4. Operating profit

	2025	2024
	€	€
Operating profit is stated after charging/(crediting):		
Depreciation of tangible assets	25,207	15,753
Government grants received	(4,767)	(5,040)
	<u>20,440</u>	<u>10,713</u>

5. Other Gains and Losses

	2025	2024
	€	€
Fair value gains and losses are as follows:		
	<u>59,379</u>	<u>(10,551)</u>

Casserly Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

continued

6. Employees

The average monthly number of employees, including director, during the financial year was 5, (2024 - 5).

	2025 Number	2024 Number
Average monthly number of other staff	1	1
Average monthly number of Pharmacists	1	1
Average monthly number of Sales Assistants	3	3
	<u>5</u>	<u>5</u>

7. Tax on profit

	2025 €	2024 €
(a) Analysis of charge in the financial year		
Current tax:		
Corporation tax at 12.50% (2024 - 12.50%) (Note 7 (b))	42,562	30,070
	<u>42,562</u>	<u>30,070</u>
(b) Factors affecting tax charge for the financial year		

The tax assessed for the financial year differs from the standard rate of corporation tax in the Republic of Ireland 12.50% (2024 - 12.50%). The differences are explained below:

	2025 €	2024 €
Profit taxable at 12.50%	376,632	217,685
Profit before tax	<u>376,632</u>	<u>217,685</u>
multiplied by the standard rate of corporation tax in the Republic of Ireland at 12.50% (2024 - 12.50%)	47,079	27,211
Effects of:		
Expenses not deductible for tax purposes	(7,233)	1,325
Depreciation in excess of capital allowances for period	2,716	1,534
Total tax charge for the financial year (Note 7 (a))	<u>42,562</u>	<u>30,070</u>

8. Tangible assets

	Land and buildings freehold €	Investment properties €	Long leasehold property €	Fixtures, fittings and equipment €	Total €
Cost					
At 1 May 2024	567,252	112,837	16,000	53,211	749,300
At 30 April 2025	<u>567,252</u>	<u>112,837</u>	<u>16,000</u>	<u>53,211</u>	<u>749,300</u>
Depreciation					
At 1 May 2024	13,236	-	16,000	29,869	59,105
Charge for the financial year	22,690	-	-	2,517	25,207
At 30 April 2025	<u>35,926</u>	<u>-</u>	<u>16,000</u>	<u>32,386</u>	<u>84,312</u>
Net book value					
At 30 April 2025	<u>531,326</u>	<u>112,837</u>	<u>-</u>	<u>20,825</u>	<u>664,988</u>
At 30 April 2024	<u>554,016</u>	<u>112,837</u>	<u>-</u>	<u>23,342</u>	<u>690,195</u>

Casserly Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

continued

9. Investments

	Listed investments	Total
	€	€
Investments		
Cost or Valuation		
At 1 May 2024	739,449	739,449
Revaluations	59,379	59,379
At 30 April 2025	<u>798,828</u>	<u>798,828</u>
Net book value		
At 30 April 2025	<u>798,828</u>	<u>798,828</u>
At 30 April 2024	<u>739,449</u>	<u>739,449</u>

10. Stocks

	2025	2024
	€	€
Finished goods and goods for resale	<u>91,352</u>	<u>91,160</u>

The replacement cost of stock did not differ significantly from the figures shown.

11. Debtors

	2025	2024
	€	€
Other debtors	66,671	67,151
Taxation	116	5,785
Prepayments	3,778	260
Accrued income	552	-
	<u>71,117</u>	<u>73,196</u>

The fair values of debtors and prepayments approximate to their carrying amounts.

12. Creditors

Amounts falling due within one year	2025	2024
	€	€
Amounts owed to credit institutions	1,290	-
Trade creditors	57,092	45,762
Taxation	9,451	8,121
Director's current account (Note 15)	958	62,799
Other creditors	1,596,185	-
Accruals	8,210	6,983
	<u>1,673,186</u>	<u>123,665</u>

The directors loan balance is owed to Evelyn Casserly and is interest free, unsecured and repayable on demand.

13. Income Statement

	2025	2024
	€	€
At 1 May 2024		
Redemption of shares	2,099,823	1,912,208
Profit for the financial year	(1,574,930)	-
	<u>334,070</u>	<u>187,615</u>
At 30 April 2025	<u>858,963</u>	<u>2,099,823</u>

Casserly Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 April 2025

continued

14. Capital commitments

The company had no material capital commitments at the financial year-ended 30 April 2025.

15. Director's remuneration and transactions

	2025	2024
	€	€
Remuneration	<u>76,000</u>	<u>70,000</u>

The following amounts are repayable to the director:

	2025	2024
	€	€
Claire Casserly	958	-
Evelyn Casserly	-	62,799
	<u>958</u>	<u>62,799</u>

The directors loan balance owed to Claire Casserly is interest free, unsecured and repayable on demand.

16. Related party transactions

The company operates from a premises at Main Street, Abbeylix which is owned by Anthony Casserly and Evelyn Casserly. Anthony Casserly and Evelyn Casserly are related to Claire Casserly who is a director and a sole shareholder of the company. These premises have been provided rent free to the company in both the current and previous year.

The remuneration disclosed under the director's remuneration note represents the total compensation paid to key management personnel.

Anthony Casserly transferred 50 shares to Evelyn Casserly on 31/12/2024 for nominal value of €1 each. Evelyn Casserly had 100 shares in total from 31/12/2024 to 27/02/25. Evelyn Casserly transferred 30 shares to Claire Casserly on 28/02/2025. Evelyn Casserly sold the remaining 70 shares back to the company for €1,575,000. The company immediately cancelled those 70 shares after buying them back.

The company was controlled jointly by Anthony Casserly and Evelyn Casserly. Anthony Casserly and Evelyn Casserly resigned from directorship on 28th February 2025.

The company is now controlled Claire Casserly who is the sole shareholder and director of the company.

17. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

18. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 12 December 2025.